MTOR and cancer: The most hotly debated and yet unresolved issue in the area of employing calorie restriction (CR) mimetics (CRMs) as anti-cancer agents with mammalian target of rapamycin (mTOR)-inhibiting activity is the relative effects of nature versus nurture, i.e., the relative contributions of systemic factors versus cancer cell-autonomous effects [1-3].